EZZ.AU EZZ Life Science Holdings Ltd
- Market cap
- AUD 14.4M
- P/E
- -
- P/B
- 0.59x
- ROE
- -76.5%
- Dividend yield
- 6.29%
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is EZZ.AU undervalued?
Graham numberThe Graham number of EZZ Life Science Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EZZ Life Science Holdings Ltd fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-76.5%), below 10%.
ROA 0/1
Return on assets (-67.8%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-177.8%) is below the industry median (-5.3%).
Revenue Growth 1/2
Revenue grew 7.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (2.0%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.6x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (6.3%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
EZZ Life Science Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, South-East Asia, and internationally. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides …
Full company profileEZZ Life Science Holdings Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EZZ Life Science Holdings Ltd annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 11.2M | 17.3M | 22.3M | 15.0M | 37.1M | 66.4M | 66.9M | 46.3M | 85.9M |
| Gross Profit | 4.36M | 3.56M | 12.5M | 7.51M | 27.2M | 50.9M | 49.7M | 25.8M | 40.9M |
| Operating Income | 1.18M | 1.48M | 2.57M | 1.64M | 4.62M | 9.72M | 9.93M | -6.61M | -26.0M |
| EBITDA | 1.18M | 2.30M | 2.87M | 1.90M | 5.09M | 10.4M | 11.1M | -6.12M | -25.0M |
| Net Income | 824K | 1.59M | 2.03M | 1.31M | 3.63M | 6.96M | 6.73M | -5.32M | -18.7M |
| EPS | 0.02 | 0.04 | 0.05 | 0.03 | 0.08 | 0.16 | 0.15 | -0.11 | -0.40 |
| Balance Sheet | |||||||||
| Total Assets | 2.91M | 11.6M | 12.0M | 14.3M | 17.6M | 25.6M | 34.0M | 27.6M | 27.6M |
| Total Liabilities | 2.09M | 3.78M | 1.93M | 2.88M | 3.06M | 4.23M | 5.87M | 3.15M | 3.15M |
| Shareholders' Equity | 824K | 7.85M | 10.1M | 11.4M | 14.6M | 21.3M | 28.1M | 24.5M | 24.5M |
| Cash & Short-term Investments | 414K | 8.41M | 8.85M | 10.5M | 13.8M | 19.0M | 20.8M | 9.72M | 9.72M |
| Total Debt | - | 32.0K | 79.0K | 105K | 479K | 124K | 304K | 479K | 479K |
| Cash Flow | |||||||||
| Operating Cash Flow | 416K | 2.97M | 254K | 1.90M | 4.01M | 6.14M | 4.35M | -8.76M | -13.1M |
| Capital Expenditure | 2.54K | 91.2K | 16.1K | 13.2K | 102K | 409K | 261K | 29.7K | 23.2K |
| Free Cash Flow | 414K | 2.88M | 237K | -13.2K | 3.91M | 5.73M | 4.09M | -8.79M | -13.1M |
| Ratios | |||||||||
| ROE | 100.0% | 20.2% | 20.1% | 11.5% | 24.9% | 32.7% | 24.0% | -21.7% | -76.5% |
| ROA | 28.3% | 13.6% | 16.9% | 9.2% | 20.6% | 27.3% | 19.8% | -19.3% | -67.8% |
| Net Profit Margin | 7.4% | 9.2% | 9.1% | 8.7% | 9.8% | 10.5% | 10.1% | -11.5% | -21.8% |
| Debt to Equity | - | 0.00x | 0.01x | 0.01x | 0.03x | 0.01x | 0.01x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EZZ Life Science Holdings Ltd dividends
- Dividend yield
- 6.29%
- Forward dividend
- 0.04 AUD
- Payout ratio
- -
- Ex-dividend date
- Nov 24, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | AUD 903K | 0.02 | - |
| 2024 | AUD 1.82M | 0.04 | 27.0% |
| 2023 | AUD 1.08M | 0.03 | 15.5% |
| 2022 | AUD 600K | 0.01 | 16.5% |
| 2021 | AUD 173K | 0.00 | 13.2% |
| 2020 | AUD 107K | 0.00 | 5.3% |
| 2019 | AUD 173K | 0.00 | 10.9% |
| 2018 | AUD 173K | 0.00 | 21.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns EZZ Life Science Holdings Ltd
- Insiders 74.10%
- Institutions 0.00%
- Public & others 25.91%
- Shares outstanding 47.1M
- Free float 12.4M
EZZ Life Science Holdings Ltd company profile
- Company name
- EZZ Life Science Holdings Ltd
- Ticker
- EZZ.AU
- ISIN
- AU0000130569
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Shop 1, 55-59 Parramatta Road, Lidcombe, NSW, Australia, 2141
- Phone
- 61 2 9160 2305
- Website
- ezzlife.com.au
About EZZ Life Science Holdings Ltd
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, South-East Asia, and internationally. The company operates through two segments, Brought in Lines and Company Owned Products. It is involved in the wholesale distribution of the EAORON branded skin care products to retailers; and direct-to-consumer distribution through e-commerce store. The company provides health and wellness products under the EZZ brand. It also offers its products online. The company was incorporated in 2015 and is based in Lidcombe, Australia.
EZZ Life Science Holdings Ltd management
6- Mr. Qizhou QinCo-Founder, COO, CEO & Executive Director
- Mr. Anthony GuarnaChief Financial Officer
- Dr. Glenn CrossChief Strategy Officer · born 1951
- Ms. Christina ChenExecutive Director
- Mr. Jay StephensonCompany Secretary
- Mr. James HudsonDirector of Corporate Affairs